Cadrenal Therapeutics, Inc. Logo

Cadrenal Therapeutics, Inc.

Developing novel anticoagulant therapies for high-risk cardiovascular patients.

CVKD | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
822 A1A NORTH, 32082 PONTE VEDRA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel anticoagulant therapies to address critical gaps in cardiovascular care. The company's mission is to create safer and more effective treatments with greater predictability and control, thereby reducing the risks of both clotting and bleeding. Its clinical-stage pipeline includes two primary assets: tecarfarin, an oral vitamin K antagonist for chronic use, and frunexian, a parenteral Factor XIa inhibitor for acute hospital settings. Cadrenal targets underserved, high-risk patient populations, including those with end-stage kidney disease and atrial fibrillation, as well as patients with implanted cardiac devices, aiming to reshape the standards of care in anticoagulation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cadrenal Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cadrenal Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cadrenal Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America AVBP
ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America AAPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.